The Food and Drug Administration has revealed that the maker of a brand of eye drops linked to an outbreak of fatal bacterial infections failed to follow multiple safety protocols.
The FDA visited a Global Pharma Healthcare facility in India for an inspection in mid-February and found dozens of issues ranging from dirty equipment and clothing to missing safeguards and procedures.
The inspection came two-and-a-half weeks after the company voluntarily recalled the EzriCare artificial tears product because of possible contamination.
When the recall was issued, there were already 55 reports of adverse events, including eye infections, permanent loss of vision, and at least one death from a bloodstream infection.
BMO Wealth Management's Carol Schleif breaks down inflation, Fed policy, earnings, AI investment, and where investors may find opportunities in today's market.
Fast Company's Christopher Zara breaks down the OpenAI-Apple legal battle, the AI chip race, and what's next for the future of artificial intelligence.
Glacier CEO Rebecca Hu-Thrams explains how AI-powered robots are making recycling smarter, reducing landfill waste, and transforming the future of waste.
Deep Fission CEO Liz Muller discusses underground nuclear reactors, powering AI, cutting energy costs, and why the future of clean power may be below ground.
Adidas shares how FIFA World Cup 2026 will drive innovation, fan engagement, and billions in opportunity with new gear, technology, and business strategy.
Kristian Kerr, Head of Macro Strategy at LPL Financial, breaks down the firm's 2026 Mid-Year Outlook, recession risks, AI, the Fed, and what's next for markets.
